Navigation Links
Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
Date:5/28/2013

NEW YORK, May 28, 2013 /PRNewswire/ -- Omthera Pharmaceuticals and AstraZeneca announced today that the companies entered into a merger agreement under which AstraZeneca will acquire all of the outstanding stock of Omthera for an upfront payment of $12.70 in cash per share, approximately $323 million aggregate value ($260 million after subtracting cash), plus a contingent value right for up to $4.70 per share, equaling approximately $120 million and for a total value of up to $443 million. Covington & Burling LLP advised Omthera on the transaction.

Omthera is an emerging specialty pharmaceutical company led by a team of experts with exceptional experience in developing new therapies for lipid disorders. Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

The Covington team was led by corporate partner Scott Smith and corporate associate Matthew Fox, with the assistance of associates Patrick Manchester, Peter Kim and Aisha Granville.  Also advising on the transaction were partner Jim Snipes (life sciences commercial), partner Mike Lefever and associate Erik Durbin (securities), partner Seth Safra and counsel Kendra Roberson (benefits), partner Mike Labson and associates Afia Asamoah and Noellyn Davies (food & drug regulatory), partner James O'Connell and associate James Burke (antitrust), and partner Rob Heller and associate Sarah Burnham (tax).

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Seoul, Shanghai, Silicon Valley, and Washington, DC.

Contact: An Pham
+1.202.662.6575
apham@cov.com


'/>"/>
SOURCE Covington & Burling LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises
2. Addressing Hearing Loss Proves Win-Win for Both Employer and Employee, BHI Advises During National Employee Wellness Month
3. Underage Kids Get Hydrocodone Drugs Easily from Family & Friends, Advises New York Center for Living
4. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
5. Apex BioStrategists Advises On Flow Cytometry Sale To Coulter
6. Intrepid Investment Bankers LLC Advises Newport Medical Instruments, Inc. in its Sale to Covidien plc
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
9. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
10. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... GREENVILLE, S.C. , Jan. 24, 2017 ... plans to release its fiscal 2017 first quarter results ... regular trading. The company will conduct a ... 3, to review the company,s financial and operating results for ... of the conference call will be available online at ...
(Date:1/24/2017)... Mich. , Jan. 24, 2017  Diplomat Pharmacy, ... the state of specialty pharmaceuticals, including a recap of ... overview of the pipeline for 2017. The ... Last year, the FDA Center for Drug Evaluation and ... was a reduction in novel new drugs compared to ...
(Date:1/24/2017)... Jan. 24, 2017  The Orthopaedic Implant Company ... high-value orthopaedic implants, announced the launch of its ... The OIC Tibial Nail System is designed ... proximal and distal screw holes accommodate varying fracture ... dynamization.  The nail is available in diameters of ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... In comments ... Research Institute (PCORI) for developing a data access and sharing policy. The nation’s ... data sharing plan as part of award applications, and earmarking specified amounts of ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... introduces more changes during the Annual Enrollment Period (AEP) and the Open Enrollment ... looking for health insurance coverage. Mainly, people are witnessing higher deductibles, rising premiums, ...
(Date:1/24/2017)... ... January 24, 2017 , ... PeroxyChem Food and ... Control Equipment (PACE), at the International Production and Processing Expo (IPPE) in Atlanta, ... the new technology that is used in poultry processing facilities to provide constant, ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... “Lacto-Freedom” was recently accepted as a Registered Trademark by the United States Patent ... using a similar name which could confuse consumers into thinking that other products ...
(Date:1/24/2017)... Estates, CA (PRWEB) , ... January 24, 2017 , ... ... at studies, work, athletics or even in relationships. Course offered by Dr. Carol ... is necessary due to limited seating and the many hands-on experiences. , ...
Breaking Medicine News(10 mins):